Top

Gepubliceerd in:

2017 | OriginalPaper | Hoofdstuk

11. Immunotherapie van kanker

Auteurs : Prof. dr. W. R. Gerritsen, Drs. H. Westdorp, Prof. dr. J. B. Haanen

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Het tijdschrift Science heeft immunotherapie van kanker uitgekozen als dé doorbraak voor 2013. Vele jaren is er geïnvesteerd in verschillende vaccinatiemethoden en de klinische resultaten waren bescheiden: enkele patiënten toonden een langdurig effect, maar bij de meeste patiënten werd geen klinische respons gevonden. De afgelopen jaren is de kennis vergroot over welke tumorantigenen immunogeen zijn, wat de functie is van antigeen presenterende cellen, zoals de dendritische cellen, hoe antigenen worden gepresenteerd aan T-cellen in locoregionale lymfeklieren, hoe T-cellen worden geactiveerd en gaan prolifereren, hoe T-cellen zich verplaatsen naar de tumoren en deze infiltreren, welke immunosuppressieve factoren (cytokines, cellen) hun functie kunnen belemmeren, en vooral hoe T-cellen in staat zijn om tumoren te doden en een langdurige respons te induceren. Deze ‘cancer-immunity cycle’ is recent beschreven door Chen en Mellman (Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10) en dient als basis voor dit hoofdstuk.

vorige hoofdstuk Basisprincipes van ‘targeted therapy’, inclusief hormonale therapie

volgende hoofdstuk Paraneoplastische syndromen

Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008;14:623–8.CrossRefPubMed

Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782–95.

Cawood R, et al. Recombinant viral vaccines for cancer. Trends in Mol Med. 2012;18(9):564–74.CrossRef

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10.CrossRefPubMed

Dotti G, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–26.CrossRefPubMed

Eertwegh AJ van den, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–17.CrossRefPubMed

Eschhar Z, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.CrossRef

Fridman WH, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298–306.

Galon J, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232:199–209.CrossRefPubMed

Hodge JW, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59(22):5800–7.

Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010a;363(8):711–23.CrossRefPubMedPubMedCentral

Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010a;363(5):411–22.CrossRefPubMed

Kantoff PW, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010b;28(7):1099–105.CrossRefPubMedPubMedCentral

Kelderman S, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014;63(5):449–58.PubMed

Kenter GG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.CrossRefPubMed

Kruit WH, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013;31(19):2413–20.CrossRefPubMed

Kwon ED, et al. Pilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.CrossRefPubMedPubMedCentral

Leach DR, et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734–6.CrossRefPubMed

Lynch TJ, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–54.CrossRefPubMed

Maus MV, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123(17):2625–35.CrossRefPubMedPubMedCentral

Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38–48.CrossRefPubMedPubMedCentral

Poelgeest MI van, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88.CrossRefPubMedPubMedCentral

Proietti E, et al. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol. 2012;6(1):1–14.CrossRefPubMed

Schreibelt et al. 2016 (effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells). Clin Cancer Res

Tel J, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013a;73(3):1063–75.CrossRefPubMed

Tel J, et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol. 2013b;191(10):5005–12.CrossRefPubMed

Tel J, et al. Tumoricidal activity of human dendritic cells. Trends Immunol. 2014;35(1):38–46.CrossRefPubMed

Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185–7.CrossRefPubMed

Vansteenkiste J, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396–403.CrossRefPubMed

Vigneron N, et al. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013;13:15.PubMedPubMedCentral

Zeestraten EC, et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013;132(7):1581–91.CrossRefPubMed

Zugmaier G et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015 Dec 10;126(24):2578–84.

Titel: Immunotherapie van kanker
Auteurs: Prof. dr. W. R. Gerritsen
Drs. H. Westdorp
Prof. dr. J. B. Haanen
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leerboek oncologie
Print ISBN: 978-90-368-0441-7

Elektronisch ISBN: 978-90-368-0442-4

Copyright: 2017
DOI: https://doi.org/10.1007/978-90-368-0442-4_11

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen